OpenURL Connection Search

Select item for more details and to access through your institution.

Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis.
Published in:
1996
By:
- Meulbroek, Jonathan A.;
- Oleksijew, Anatol;
- Tanaka, S. Ken;
- Alder, Jeffrey D.;
- Meulbroek, J A;
- Oleksijew, A;
- Tanaka, S K;
- Alder, J D
Publication type:
journal article
Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.
Published in:
Pharmacology Research & Perspectives, 2015, v. 3, n. 5, p. 1, doi. 10.1002/prp2.178
By:
- Ackler, Scott;
- Oleksijew, Anatol;
- Chen, Jun;
- Chyla, Brenda J.;
- Clarin, Jerry;
- Foster, Kelly;
- McGonigal, Thomas;
- Mishra, Sasmita;
- Schlessinger, Sally;
- Smith, Morey L.;
- Tahir, Stephen K.;
- Leverson, Joel D.;
- Souers, Andrew J.;
- Boghaert, Erwin R.;
- Hickson, Jonathan
Publication type:
Article
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Published in:
2016
By:
- Jieyi Wang;
- Goetsch, Liliane;
- Tucker, Lora;
- Qian Zhang;
- Gonzalez, Alexandra;
- Vaidya, Kedar S.;
- Oleksijew, Anatol;
- Boghaert, Erwin;
- Minghao Song;
- Sokolova, Irina;
- Pestova, Ekaterina;
- Anderson, Mark;
- Pappano, William N.;
- Ansell, Peter;
- Bhathena, Anahita;
- Naumovski, Louie;
- Corvaia, Nathalie;
- Reilly, Edward B.;
- Wang, Jieyi;
- Zhang, Qian
Publication type:
journal article
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.
Published in:
Pharmacology, 2017, v. 100, n. 5/6, p. 229, doi. 10.1159/000478663
By:
- Vaidya, Kedar S.;
- Oleksijew, anatol;
- Tucker, Lora a.;
- Pappano, William N.;
- anderson, Mark G.;
- Grinnell, Christine M.;
- Zhang, Qian;
- Heighton, Sarah J.;
- Mitten, Michael J.;
- Mishra, Sasmita;
- Palma, Joann P.;
- Wang, Jieyi;
- Reilly, Edward B.;
- Boghaert, Erwin R.
Publication type:
Article
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Published in:
Science Translational Medicine, 2015, v. 7, n. 279, p. 1, doi. 10.1126/scitranslmed.aaa4642
By:
- Leverson, Joel D.;
- Phillips, Darren C.;
- Mitten, Michael J.;
- Boghaert, Erwin R.;
- Diaz, Dolores;
- Tahir, Stephen K.;
- Belmont, Lisa D.;
- Nimmer, Paul;
- Yu Xiao;
- Xiaoju Max Ma;
- Lowes, Kym N.;
- Kovar, Peter;
- Jun Chen;
- Sha Jin;
- Smith, Morey;
- Xue, John;
- Haichao Zhang;
- Oleksijew, Anatol;
- Magoc, Terrance J.;
- Vaidya, Kedar S.
Publication type:
Article
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Published in:
Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 5, p. 869, doi. 10.1007/s00280-009-1232-1
By:
- Ackler, Scott;
- Mitten, Michael J.;
- Foster, Kelly;
- Oleksijew, Anatol;
- Refici, Marion;
- Tahir, Stephen K.;
- Yu Xiao;
- Tse, Christin;
- Frost, David J.;
- Fesik, Stephen W.;
- Rosenberg, Saul H.;
- Elmore, Steven W.;
- Shoemaker, Alexander R.
Publication type:
Article
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Published in:
Journal of Neuro-Oncology, 2021, v. 152, n. 2, p. 233, doi. 10.1007/s11060-021-03703-z
By:
- Vaidya, Kedar S.;
- Mitten, Michael J.;
- Zelaya-Lazo, Adelyn L.;
- Oleksijew, Anatol;
- Alvey, Cory;
- Falls, Hugh D.;
- Mishra, Sasmita;
- Palma, Joann;
- Ansell, Peter;
- Phillips, Andrew C.;
- Reilly, Edward B.;
- Anderson, Mark;
- Boghaert, Erwin R.
Publication type:
Article

Found: 7

Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis.

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.